<DOC>
	<DOCNO>NCT00034450</DOCNO>
	<brief_summary>L-carnitine supplement ( type vitamin ) suggest decreased patient cancer . We identify patient terminal cancer fatigue . The purpose study determine L-carnitine replacement improve fatigue cancer patient L-carnitine deficiency .</brief_summary>
	<brief_title>Developmental Study Fatigue Cancer</brief_title>
	<detailed_description>Fatigue frequently report symptom patient cancer . The cause fatigue multifactorial include disease , antineoplastic therapy , anemia , depression , malnutrition . Our preliminary data suggest micronutrient deficiency , specifically carnitine deficiency , may important factor fatigue . Carnitine play major role energy metabolism . Systemic depletion characterize weight loss , fatigue , muscle weakness , decrease tolerance metabolic stress , cardiomyopathy . We find deficiency micronutrient carnitine 17/27 patient cancer . Symptoms fatigue functional status improve significantly patient receive oral L-carnitine supplementation . In addition , observe similar result 6/10 patient end stage AIDS presenting carnitine deficiency . Objectives : ) To determine effect L-carnitine therapy symptom fatigue patient terminal cancer serum carnitine deficiency , b ) determine effect L-carnitine therapy performance status , cognitive function , mood , quality life , motor activity patient . Study Design : We propose conduct Phase Il developmental randomize double-blind placebo-controlled study determine effect micronutrient L-carnitine fatigue outcomes patient terminal cancer . A sample 130 patient terminal cancer , fatigue serum carnitine deficiency recruit intervention study . At first visit , patient receive baseline assessment fatigue , performance status , cognitive function , mood , quality life motor activity . ) During week 1-4 , patient randomize receive L-carnitine , 2 g/day , placebo . b ) During week 5-8 , patient receive L-carnitine dose 2 g/day , period 4 week . Measures repeat 48 h , 2 week , 4 week 8 week . The primary endpoint change fatigue 4 week . Analysis evaluate group difference primary endpoint outcome . An interim analysis do 15 patient observe group 4 week . Paired unpaired data analysis group conduct assistance statistician .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<criteria>Inclusion : Patients diagnosis cancer estimate life expectancy le 6 month . Patients undergone antineoplastic therapy may worsen fatigue promote carnitine deficiency eligible complete therapy 90 day prior begin study . Exclusion : Uncontrolled severe cardiovascular , pulmonary , renal disease . Patients encephalopathy psychiatric disorder sufficiently severe impair completion questionnaire . Treatment replacement therapy form carnitine le 12 month prior enrollment . Known sensitivity carnitine . History seizures stroke .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Terminal Cancer</keyword>
</DOC>